National Cancer Institute (NCI) Researchers Provide Details of New Studies and Findings in the Area of Xenografts (Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in...).

A recent report from the National Cancer Institute (NCI) discusses the issue of gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC), a highly lethal form of cancer. The researchers reanalyzed gene expression profiles of PDAC patient-derived xenograft (PDX) models before and after gemcitabine treatment to identify molecular markers of resistance. They found that upregulation of both glycolysis and oxidative phosphorylation pathways occurred in PDAC PDXs following gemcitabine treatment, and that pathogenic TP53 mutations were associated with resistance. These findings may help to better understand gemcitabine resistance and inform the development of effective drug combinations for PDAC chemotherapy. [Extracted from the article]